Embryo research and stem cells in France: What might change?

Every seven years, French lawmakers are handed a difficult exercise: to debate how far we should collectively reach into the frontiers of scientific knowledge. Each successive bioethics law sets the date of its next revision, so that legislation keeps pace with social and technological change.

The latest round of revision has just started, and among the first to weigh in is a French parliamentary science advisory body – the Office Parlementaire d'Évaluation des Choix Scientifiques et Technologiques (OPECST). In June 2026, OPECST published a report evaluating the implementation of the 2021 Bioethics Act and making recommendations for reform, pursuant to article 41 of the Act.

The OPECST report sets out 82 recommendations on topics as varied as organ donation, xenotransplantation, assisted reproduction, direct-to-consumer genetic testing, surrogacy, in vitro gametogenesis, neurotechnologies and AI in healthcare. Here, we focus on human embryo research – in particular, the 14-day limit on human embryo culture – and on stem-cell-based embryo models (SCBEMs).

The legal and regulatory framework

Since 2021, France has had a framework dedicated specifically to stem cell research, alongside its longstanding regulation of embryo research. All human embryonic stem (hES) cell protocols must be reported to the Agence de la Biomédecine (ABM), which then has two months to object to any protocol that does not meet legal requirements.

Articles L2151-6 and L2151-7 of the French Public Health Code mandate reporting of whether human SCBEMs – referred to in French law as 'in vitro models of embryonic development' (modèles de développement embryonnaire in vitro) – are derived from hES cells, or from induced pluripotent stem cells.

The ABM checks whether general bioethical principles such as human dignity, non-commercialisation and donor consent are respected. The ABM's Orientation Council is also consulted on SCBEM protocols, in which case the objection period is extended to four months.

In September 2023, the Orientation Council published a standalone opinion on SCBEMs, addressing what sets SCBEM apart from embryos. In the Council's view, SCBEMs are not embryos for two main reasons:

• They originate from stem cells, rather than from fertilisation of an egg cell by a sperm cell.
• They are not created in the context of a parental project.

The Council proposed the following three principles for reviewing SCBEM protocols:

• Proportionality – weighing risks and benefits against the research objectives.
• Subsidiarity – using only the means that are strictly necessary to fulfil the research objectives.
• Precaution – taking proportionate measures against serious and irreversible harm where scientific knowledge is lacking.

The Council also proposed limiting the culture of SCBEMs to the equivalent of 28 days of human embryo development. The Council argued that beyond this point, other models become available, while SCBEMs become decreasingly similar to natural human embryos.

The role of OPECST

Created in 1983, OPECST is a parliamentary committee composed of members of both chambers of the French Parliament (the National Assembly and the Senate). Its mission is to inform Parliament of the implications of scientific and technological choices.

OPECST regularly publishes reports on environmental/energy policy, research/innovation policy, life sciences and biotechnology. OPECST leans heavily on the opinions of the ABM's Orientation Council, while also adopting its own positions (not always consistently).

The 14-day limit

The internationally recognised 14-day limit on human embryo culture was written into French law in 2021, but it has come under growing scrutiny. Culture methods can now sustain embryos past 14 days and the International Society for Stem Cell Research has dropped its hard cap, leaving each country to decide whether to keep or relax the rule (see BioNews 1097). OPECST recommends extending the limit 'beyond 14 days, on an exceptional and gradual basis between the 15th and 21st days.'

This is not a new proposal. During the last revision of the law, senators proposed an exceptional extension to 21 days for gastrulation research, in order to anticipate international developments and keep French research competitive. However, the National Assembly struck down this proposal, arguing that it was too hasty and too risky for embryonic life. The ABM's Orientation Council also opposed going beyond 14 days, pointing to SCBEMs as an alternative for studying gastrulation and later stages.

As with any legislative reform, not all actors agree, and much can still change. At the very least, the 21-day figure requires better justification than is offered by the OPECST report, since the report does not explain how OPECST arrived at this number.

Creating human embryos for research

OPECST recommends keeping the current French ban on creating human embryos specifically for research – a ban which has been in place since 1994.

Several institutions have already opened discussion on this issue (for example here and here), but what is often left out of these discussions is that France is internationally bound to this ban, because France not only signed but also ratified the Oviedo Convention. This means that even if there were sufficient political will to lift the ban domestically, doing so would put France in breach of a binding international commitment, and would risk condemnation before the European Court of Human Rights.

Stem-cell-based embryo models

France was among the first countries to legislate on SCBEMs, requiring their declaration to the ABM from 2021. Despite researchers creating SCBEMs that are increasingly faithful to later stages of embryonic and fetal development, OPECST deems the existing notification regime 'sufficient' and recommends against creating a specific framework.

At the same time, OPECST recommends applying a 21-day limit to SCBEM culture, and writing this limit into law. In other words, despite concluding that no regulatory change is needed, the OPECST report nonetheless proposes aligning SCBEMs with the 21-day limit suggested for embryos.

This raises several concerns and leaves some important questions unanswered:

• OPECST seems to have assumed that the existing 14-day rule for embryos also applies to SCBEMs, which has never been the case in French law or in ABM practice.
• OPECST does not explain where its choice of 21 days comes from. Indeed, it is notable that other French and foreign bodies cited in the report appear to be converging on a 28-day limit, based on considerations such as the onset of organogenesis and the availability of alternative models.
• What exactly counts as a SCBEM, if the boundary between SCBEMs and organoids becomes blurred?
• How should the developmental days of SCBEMs be counted, when SCBEMs do not begin with fertilisation, and when they develop at varying rates?

What happens next?

The OPECST report is just one of several institutional contributions that are expected ahead of the next revision of French bioethics law.

The Comité Consultatif National d'Éthique (CCNE), a French national ethics committee, has already held a public consultation and has summarised its findings in a June 2026 report. The report's section on organoids and SCBEMs finds broad public support for organoid research, but public concern about SCBEMs and brain organoids, suggesting that the consent framework needs to be revised. The CCNE is also expected to publish its own opinion on the revision by the end of 2026.

Further reports on these matters are likely to appear, notably from the Conseil d'État and from the national professional academies. However, the fact that 2027 is an election year in France means that the government and Parliament are unlikely to give much attention to the reform of bioethics law.

The formal revision process will only begin once the government tables a bill in Parliament. Until then, the OPECST report is best read as one voice among several, in a conversation that is still unfolding.

This work has been supported by the ANR-funded Organact project (ANR-22-CE41-0012). Thanks to Anne Le Goff and Maxence Gaillard for their comments.